

Jake S O'donnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8598685/publications.pdf>

Version: 2024-02-01

15
papers

3,266
citations

623734

14
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

5938
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor intrinsic and extrinsic immune functions of CD155. <i>Seminars in Cancer Biology</i> , 2020, 65, 189-196.	9.6	85
2	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020, 180, 895-914.e27.	28.9	127
3	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	7.0	53
4	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019, 25, 5743-5751.	7.0	129
5	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. <i>Oncolimmunology</i> , 2019, 8, e1581530.	4.6	69
6	Batf3 ⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. <i>Oncolimmunology</i> , 2019, 8, e1546068.	4.6	42
7	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	27.6	1,093
8	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. <i>Oncolimmunology</i> , 2018, 7, e1431088.	4.6	67
9	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	9.6	257
10	PD1 functions by inhibiting CD28-mediated co-stimulation. <i>Clinical and Translational Immunology</i> , 2017, 6, e138.	3.8	15
11	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81.	7.7	437
12	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	14.3	207
13	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. <i>Cancer Discovery</i> , 2016, 6, 1382-1399.	9.4	592
14	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. <i>Genome Medicine</i> , 2016, 8, 111.	8.2	59
15	The voltage gated Ca ²⁺ -channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016, 16, 24.	4.1	34